NICE throws a wrench in Takeda's Ninlaro growth plans with second rejection
admin 6th September 2017 Uncategorised 0Last year, Takeda CEO Christophe Weber told investors that multiple myeloma med Ninlaro would surpass blockbuster Velcade as the company’s biggest-ever cancer product. But for now, it looks like it’ll have to do it without the help of England’s NHS.
More: NICE throws a wrench in Takeda's Ninlaro growth plans with second rejection
Source: fierce